September 12, 2002Journal of Clinical Oncology
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
Authors
Discussion
Loading...
Member takes
Implication
Key Points
Key points are not available for this paper at this time.
Cite This Study
Herbst et al. (2002) studied this question.